AIT-082 NeoTherapeutics Inc Hugo Geerts
NeoTherapeutics as a potential treatment for Alzheimer's ..... 279422 NeoTherapeutics to begin new phase of AIT-082 testing ...
http://www.biomedcentral.com/content/pdf/cd-470252.pdf...
|
BioPortfolio - neotherapeutics irvine, ca
neotherapeutics irvine, ca - BioPortfolio. ... Mark M. Foreman has been named by NeoTherapeutics (Irvine, CA) as its senior director of research. ...
http://www.bioportfolio.com/search/neotherapeutics_irvine,_c...
|
AIT-082 (NeoTherapeutics Inc).
AIT-082 (an analog of hypoxanthine) is an orally-active nerve growth factor (NGF ) agonist under development by NeoTherapeutics as a potential treatment for ...
http://www.ncbi.nlm.nih.gov/pubmed/18465624...
|
BioPortfolio - BioPortfolio - NeoTherapeutics Incorporated
BioPortfolio - NeoTherapeutics Incorporated - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/linkout/7443/www.ne...
|
Miracles and molecules—progress in spinal cord repair - Nature ...
A smaller multi-center trial of Neotrofin (AIT-082), a synthetic purine, was sponsored recently by NeoTherapeutics in the US, with the proposal that this ...
http://www.nature.com/neuro/journal/v5/n11s/full/nn939.html...
|
A Glimmer of Hope for Neotrofin
In late April, NeoTherapeutics (NASDAQ: NEOT) announced that Neotrofin did not ... Even if Neotrofin can demonstrate clinical benefit, NeoTherapeutics faces
...
http://www.bioportfolio.com/news/btech_053102_1.htm...
|
Effect of a memory-enhancing drug, AIT-082, on the...[Ann N Y Acad ...
PC12 cells were treated with nerve growth factor (NGF) (50 ng/ml) and/or different doses of AIT-082 (5-50 ng/ml) obtained from NeoTherapeutics, CA. ...
http://www.ncbi.nlm.nih.gov/pubmed/10818529...
|
BioPortfolio - Biocorporate Search Obesity 1
NeoTherapeutics Incorporated is a development stage biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs intended ...
http://www.bioportfolio.com/biocorporate/Obesity%20%20-compa...
|
Vaccine tests key Alzheimer's disease hypothesis - Nature ...
NeoTherapeutics and others are hoping to convince regulators to accept ... NeoTherapeutics' Shrotrija says that there will be "no magic bullet" for ...
http://www.nature.com/nbt/journal/v19/n2/full/nbt0201_104.ht...
|
A phase I study of AIT-082 in healthy elderly volu...[J Mol ...
A Phase I, double-blind, placebo-controlled, single-dose, escalation study of the purine derivative, AIT-082 (Neotrofin, NeoTherapeutics, Inc.) was ...
http://www.ncbi.nlm.nih.gov/pubmed/12059047...
|
